Mycobacterial and Plasmodium ovale‐associated destruction of the jaw bones

Oral Diseases ◽  
2020 ◽  
Author(s):  
Xianrui Yang ◽  
Adam Yongxin Ye ◽  
Negin Katebi ◽  
Vladimir Volloch ◽  
Shelley M. Khullar ◽  
...  
Keyword(s):  
2012 ◽  
Vol 2 (1) ◽  
pp. 51 ◽  
Author(s):  
SeJin Moon ◽  
Baek-Nam Kim ◽  
Eun-Young Kuak ◽  
Tae Hee Han
Keyword(s):  

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Tao Zhang ◽  
Shuqi Wang ◽  
Duoquan Wang ◽  
Sarah Auburn ◽  
Shenning Lu ◽  
...  

Abstract Background Although autochthonous malaria cases are no longer reported in Anhui Province, China, imported malaria has become a major health concern. The proportion of reported malaria cases caused by Plasmodium ovale spp. increased to levels higher than expected during 2012 to 2019, and showed two peaks, 19.69% in 2015 and 19.35% in 2018. Methods A case-based retrospective study was performed using data collected from the China Information System for Disease Control and Prevention (CISDCP) and Information System for Parasitic Disease Control and Prevention (ISPDCP) from 2012 to 2019 to assess the trends and differences between Plasmodium ovale curtisi (P. o. curtisi) and Plasmodium ovale wallikeri (P. o. wallikeri). Epidemiological characteristics were analyzed using descriptive statistics. Results Plasmodium o. curtisi and P. o. wallikeri were found to simultaneously circulate in 14 African countries. Among 128 patients infected with P. ovale spp., the proportion of co-infection cases was 10.16%. Six cases of co-infection with P. ovale spp. and P. falciparum were noted, each presenting with two clinical attacks (the first attack was due to P. falciparum and the second was due to P. ovale spp.) at different intervals. Accurate identification of the infecting species was achieved among only 20.00% of cases of P. ovale spp. infection. At the reporting units, 32.17% and 6.96% of cases of P. ovale spp. infection were misdiagnosed as P. vivax and P. falciparum infections, respectively. Conclusion The present results indicate that the potential of P. ovale spp. to co-infect with other Plasmodium species has been previously underestimated, as is the incidence of P. ovale spp. in countries where malaria is endemic. P. o. curtisi may have a long latency period of > 3 years and potentially cause residual foci, thus posing challenges to the elimination of malaria in P. ovale spp.-endemic areas. Considering the low rate of species identification, more sensitive point-of-care detection methods need to be developed for P. ovale spp. and introduced in non-endemic areas.


2014 ◽  
Vol 58 (6) ◽  
pp. 3354-3359 ◽  
Author(s):  
Sasithon Pukrittayakamee ◽  
Joel Tarning ◽  
Podjanee Jittamala ◽  
Prakaykaew Charunwatthana ◽  
Saranath Lawpoolsri ◽  
...  

ABSTRACTChloroquine combined with primaquine has been the standard radical curative regimen forPlasmodium vivaxandPlasmodium ovalemalaria for over half a century. In an open-label crossover pharmacokinetic study, 16 healthy volunteers (4 males and 12 females) aged 20 to 47 years were randomized into two groups of three sequential hospital admissions to receive a single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together. The coadministration of the two drugs did not affect chloroquine or desethylchloroquine pharmacokinetics but increased plasma primaquine concentrations significantly (P≤ 0.005); the geometric mean (90% confidence interval [CI]) increases were 63% (47 to 81%) in maximum concentration and 24% (13 to 35%) in total exposure. There were also corresponding increases in plasma carboxyprimaquine concentrations (P≤ 0.020). There were no significant electrocardiographic changes following primaquine administration, but there was slight corrected QT (QTc) (Fridericia) interval lengthening following chloroquine administration (median [range] = 6.32 [−1.45 to 12.3] ms;P< 0.001), which was not affected by the addition of primaquine (5.58 [1.74 to 11.4] ms;P= 0.642). This pharmacokinetic interaction may explain previous observations of synergy in preventingP. vivaxrelapse. This trial was registered at ClinicalTrials.gov under reference number NCT01218932.


1976 ◽  
Vol 5 (4) ◽  
pp. 166-171 ◽  
Author(s):  
Masahito Sugimura ◽  
Yoshio Kashibayashi ◽  
Isao Ban ◽  
Kensaku Kawakatsu ◽  
Masahiro Tsubakimoto

2014 ◽  
Vol 13 (1) ◽  
Author(s):  
Cécile Doderer-Lang ◽  
Pascal S Atchade ◽  
Lydia Meckert ◽  
Elodie Haar ◽  
Sylvie Perrotey ◽  
...  

2015 ◽  
Vol 14 (1) ◽  
Author(s):  
Pedro Berzosa Díaz ◽  
Patricia Mula Lozano ◽  
Jose Manuel Ramos Rincón ◽  
Luz García ◽  
Francisco Reyes ◽  
...  

2021 ◽  
Vol 23 (10) ◽  
pp. 1393-1403
Author(s):  
Felix Ansah ◽  
Jonathan Suurbaar ◽  
Derrick Darko ◽  
Nsoh G. Anabire ◽  
Samuel O. Blankson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document